TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16580444
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate administered to increase plasma levels 1(1/2) to 2 times normal during cardiopulmonary bypass, n = 174
Study: 10902991
Drug: Control (M)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (M) = 12 mg iron + 209 kJ
Study: 8436004
Drug: Medical termination
Normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical termination of pregnancy with mifepristone (200 mg) and gemeprost (1 mg)
Study: 8436004
Drug: Medical termination
Normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical termination of pregnancy with mifepristone (400 mg) and gemeprost (1 mg)
Study: 8436004
Drug: Medical termination
Normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical termination of pregnancy with mifepristone (600 mg) and gemeprost (1 mg)
Study: 2992530
Drug: suloctidil (Locton)
Normalized name: suloctidil
DrugBank: Suloctidil (DB13340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: suloctidil (Locton) at a daily dose of 200 mg X 3 for 180 days
Study: 22891564
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (average 18.47 +/- 8.81 mCi)
Study: 22891564
Drug: Thiamazole treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamazole treatment before radioiodine therapy
Study: 18550953
Drug: Concurrent strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent strength and endurance (CSE) training
Study: 7584685
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms once or twice daily
Study: 7584685
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray (BPD) 200 micrograms twice daily
Study: 17520566
Drug: Regional heparinization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional heparinization (heparin 1500 IU/h pre-filter, protamine 15 mg/h post-filter)
Study: 17520566
Drug: Regional citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional citrate anticoagulation (citrate-based replacement fluid 14 mmol/L pre-dilution)
Study: 11114960
Drug: Cholestyramine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (6 g three times a day)
Study: 19332518
Drug: Parotid gland-sparing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parotid gland-sparing intensity-modulated radiation therapy (IMRT)
Study: 17897465
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone for 12 months
Study: 9793844
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy with captopril (75 mg/day, n = 13)
Study: 9793844
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy with nifedipine (40 mg/day, n = 12)
Study: 7894825
Drug: Artemether administered
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether administered intramuscularly twice daily (1.6 or 3.2 mg/kg/day)
Study: 2558817
Drug: Soluble insulin
Normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble insulin 0.15U/kg
Study: 2558817
Drug: Soluble insulin
Normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble insulin 0.15U/kg followed by oCRF41 100 micrograms
Study: 344108
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (C.p.) 5 mg/sc/m2 on day 1 in addition to CAO/CMF
Study: 30598342
Drug: Solriamfetol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol (300 mg) in fasted condition
Study: 30598342
Drug: Solriamfetol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol (300 mg) in fed condition
Study: 17459480
Drug: LTFC (Latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTFC (Latanoprost and Timolol Fixed Combination)
Study: 11704081
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light therapy (DLT)
Study: 8199567
Drug: High-dose cyclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclosporin (CsA)
Study: 8199567
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin (CsA)
Study: 3587902
Drug: Concurrent multiagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent multiagent chemotherapy and orbital radiation therapy after initial partial tumor resection
Study: 29606517
Drug: F4/AS01B HIV-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: F4/AS01B HIV-1 vaccine candidate
Study: 20802351
Drug: AZD6244 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6244 (100 mg oral free-base suspension twice daily)
Study: 20802351
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 intravenous once every 3 weeks)
Study: 19054833
Drug: Nicotinell TTS
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinell TTS 20 patch (single dose)
Study: 19054833
Drug: Nicotinell TTS
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinell TTS 20 patch (multiple doses over 4 days)
Study: 14646626
Drug: Cisplatin at
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin at a dose of 150 mg/m2 and WR‐2721 at a dose of 910 mg/m2
Study: 14646626
Drug: Cisplatin alone
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin alone at a dose of 120 mg/m2
Study: 10671837
Drug: Background infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background infusion of 5 ml x h‐1 (Group B)
Study: 10671837
Drug: No background
Approvals — FDA: no, EMA: no, PMDA: no
Description: No background infusion (Group N)
Study: 8826489
Drug: Topical aspirin/diethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aspirin/diethyl ether (ADE) mixture
Study: 1594261
Drug: Indomethacin and
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin and diclofenac drug/ether mixtures
Study: 6705752
Drug: Flunarizine (add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (add-on therapy)
Study: 14504005
Drug: Alprostadil 500
Normalized name: ALPROSTADIL 500MCG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil 500 g cream
Study: 14504005
Drug: Alprostadil 1000
Normalized name: ALPROSTADIL 1000MCG SUPP,URETHRAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil 1000 g cream
Study: 14504005
Drug: Alprostadil 1500
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil 1500 g cream
Study: 10348802
Drug: Single-dose disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose disulfiram
Study: 8547045
Drug: 8-methoxypsoralen (8-MOP)
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-methoxypsoralen (8-MOP) calculated according to body weight (0.6 mg/kg)
Study: 8547045
Drug: 8-methoxypsoralen (8-MOP)
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-methoxypsoralen (8-MOP) calculated according to body surface area (25 mg/m2)
Study: 8547045
Drug: 8-methoxypsoralen (8-MOP)
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-methoxypsoralen (8-MOP) doses of 40 or 50 mg based on body surface area
Study: 7017074
Drug: 10% ointment
Normalized name: Tiger Balm Red Extra Strength 11%-10% Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% ointment from 95% ethanol extract of Lupinus termis seeds
Study: 7017074
Drug: 0.02% flumethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% flumethasone pivalate ointment
Study: 30577819
Drug: Immediate Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate Intervention (n=30) received a Fitbit® Flex™ and four bi-weekly activity counselling sessions
Study: 22500821
Drug: Pegnivacogin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegnivacogin 0.5 mg kg(‐1)
Study: 22500821
Drug: Pegnivacogin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegnivacogin 1.0 mg kg(‐1)
Study: 22500821
Drug: Pegnivacogin 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegnivacogin 3.0 mg kg(‐1)
Study: 22500821
Drug: Pegnivacogin 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegnivacogin 2.0 mg kg(‐1)
Study: 22500821
Drug: Anivamersen (single-dose)
Normalized name: Anivamersen
DrugBank: Anivamersen (DB16089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anivamersen (single-dose)
Study: 20399240
Drug: DTaP/Hib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP/Hib combination vaccine (3 doses at 3, 4, and 5 months)
Study: 20399240
Drug: Separate licensed
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate licensed DTaP vaccine and Hib conjugate vaccine (3 doses at 3, 4, and 5 months)
Study: 8806255
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with antiretroviral drugs
Study: 1988512
Drug: Bivalent attenuated
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent attenuated (CR) vaccine
Study: 1988512
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated (TI) vaccine
Study: 24555576
Drug: PDE-5 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE-5 inhibitors in adequately blinded trials
Study: 24555576
Drug: PDE-5 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE-5 inhibitors in inadequately blinded trials
Study: 16216094
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg dose of inhaler (powder inhaler)
Study: 16216094
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg dose of inhaler (remaining powder)
Study: 2150105
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (first- or second-generation cephalosporins)
Study: 6941373
Drug: Combined injection
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined injection of 3.0 mg/kg cimetidine and 0.3 mg/kg pirenzepine
Study: 6941373
Drug: Combined injection
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined injection of 1.5 mg/kg cimetidine, 0.075 and 0.15 mg/kg pirenzepine
Study: 31286732
Drug: Umbilical needling
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical needling therapy of I-Ching; treatment at 1 PM to 3 PM, once a day for 20 days.
Study: 31286732
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment of western medicine combined with TCM decoction; control group.
Study: 25769541
Drug: Continuous lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous lenalidomide and low-dose dexamethasone
Study: 25769541
Drug: Fixed cycles
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed cycles of lenalidomide and low-dose dexamethasone for 18 months
Study: 21500011
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity (three times weekly)
Study: 21500011
Drug: Mental activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental activity (three times weekly)
Study: 14984440
Drug: Betamethasone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (60 mg)
Study: 14984440
Drug: Methylprednisolone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (400 mg)
Study: 9342783
Drug: Melatonin (MLT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (MLT; 3 mg)
Study: 9342783
Drug: Melatonin (MLT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (MLT; 9 mg)
Study: 9342783
Drug: Melatonin (MLT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (MLT; 3 mg or 9 mg)
Study: 4041370
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A in combination with antilymphocyte serum
Study: 29561377
Drug: 4.5-mm-wide titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5-mm-wide titanium implant
Study: 29561377
Drug: 3.75-mm-wide titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75-mm-wide titanium implant
Study: 21613553
Drug: Yogurt consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt consumption >100 g/d
Study: 19549290
Drug: Masitinib 3
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Masitinib 3 mg/kg per day
Study: 19549290
Drug: Masitinib 6
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Masitinib 6 mg/kg per day
Study: 9038130
Drug: Gd‐EOB‐DTPA (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd‐EOB‐DTPA (12.5, 25, or 50 micromol/kg body weight) administered as an IV bolus
Study: 7912123
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin 7.5 g every 4 weeks for 1 year
Study: 7912123
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin 40 g every 4 weeks for 1 year
Study: 7912123
Drug: Standard HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HIV treatment (control group)
Study: 28554910
Drug: Twice-daily supportive
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily supportive SMS text messages for 6 months plus treatment as usual
Study: 22924260
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) with energy dose of 0.1 J per point
Study: 22924260
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) with energy dose of 1 J per point
Study: 22924260
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) with energy dose of 4 J per point
Study: 12878619
Drug: Tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1 mg kg(‐1))
Study: 12878619
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg kg(‐1))
Study: 12878619
Drug: Saline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (2 ml)
Study: 10381027
Drug: Two methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two methods (self-completion and interviewer administration)
Study: 10381027
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in method of administration
Study: 3578852
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% bupivacaine with 1:300,000 epinephrine
Study: 31674058
Drug: VIT-2763 5/15/60/120/240
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIT-2763 5/15/60/120/240 mg (SAD phase)
Study: 31674058
Drug: VIT-2763 60/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIT-2763 60/120 mg once daily (MAD phase)
Study: 31674058
Drug: VIT-2763 60/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIT-2763 60/120 mg twice daily (MAD phase)
Study: 31674058
Drug: VIT-2763 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIT-2763 (all doses)
Study: 31674058
Drug: VIT-2763 120
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VIT-2763 120 mg once daily (MAD phase)
Study: 27893567
Drug: Usual ambulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual ambulatory physical therapy (PT) (n = 43).
Study: 26293170
Drug: adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adapalene gel with the active formulation
Study: 26293170
Drug: adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adapalene gel with the placebo
Study: 26293170
Drug: adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adapalene gel
Study: 12915819
Drug: Ganciclovir therapy
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir therapy (6 weeks of intravenous ganciclovir)
Study: 12915819
Drug: Ganciclovir therapy
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir therapy
Study: 10574621
Drug: Neutrophil-derived serine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutrophil-derived serine proteases (elastase, cathepsin G, proteinase 3)
Study: 10574621
Drug: Cathepsin G
Normalized name: Cathepsin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathepsin G
Study: 29893769
Drug: Palbociclib 125
Normalized name: palbociclib 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 125 mg daily for 14 days
Study: 20167446
Drug: Cooled water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooled water pillow (15 degrees C) for 48 hours with restricted activity and medication (60 mg of prednisone for 7 days)
Study: 20167446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only medication (60 mg of prednisone for 7 days) without cooling and rest
Study: 12566475
Drug: Protein Group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein Group (1.6 g/(kg. d); CHO <40% of energy)
Study: 12566475
Drug: CHO Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO Group (0.8 g/(kg. d); CHO >55%)
Study: 1912753
Drug: Naltrexone (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (350 mg per week for 1 month, then random allocation to naltrexone for 6 months)
Study: 6756833
Drug: 40-g/day vegetable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-g/day vegetable protein diet
Study: 6756833
Drug: 80-g/day vegetable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-g/day vegetable protein diet
Study: 6756833
Drug: 40-g/day meat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-g/day meat protein diet plus neomycin-milk of magnesia
Study: 26111609
Drug: Enoxaparin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (20 mg, subcutaneous, every 12 h from postoperative day 2 to 8)
Study: 21390056
Drug: Indapamide slow
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide slow release 1.5 mg, indapamide plus 2 mg perindopril, and indapamide plus 4 mg perindopril
Study: 21390056
Drug: Indapamide plus
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide plus 2 mg perindopril
Study: 21390056
Drug: Indapamide plus
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide plus 4 mg perindopril
Study: 17688720
Drug: Calculated intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated intravenous crystalloid based on body weight (group 2)
Study: 8059811
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg three times a day for 7 days)
Study: 2648511
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isoniazid, rifampicin, and pyrazinamide (fixed proportions)
Study: 2648511
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of isoniazid, rifampicin, and pyrazinamide
Study: 5338884
Drug: Ro 4‐5360,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 4‐5360, 10 mg. (Mogadon)
Study: 5338884
Drug: methyprylon, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyprylon, 200 mg. (Noludar)
Study: 5338884
Drug: Ro 4‐5360,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 4‐5360, 5 mg. (Mogadon)
Study: 5338884
Drug: secobarbital sodium,
Normalized name: Secobarbital Sodium, 50 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: secobarbital sodium, 100 mg. (Seconal)
Study: 28455295
Drug: Low stroke
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low stroke volume indexed for body surface area (SVI) defined as <35 mL/m2
Study: 23716516
Drug: Hydration (drank
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration (drank 250 mL of water at 15‐minute intervals, totaling 1000 mL/h)
Study: 16779972
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish applied to experimental dental quadrants every 3 months during 12 months of orthodontic treatment
Study: 14699594
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (PE) treatment for one or two consecutive sessions